Clinical Trials Logo
  1. Home
  2. Vaccine Response Impaired
  3. NCT04059991

Antibodies in Repeated Influenza Vaccination (ARIVA) Study — ARIVA  

Vaccine Response Impaired Clinical Trial

Official title:
Antibodies in Repeated Influenza Vaccination (ARIVA) Study

Clinical Trial Summary

Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy. The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04059991
Study type Observational
Source University Hospital, Basel, Switzerland
Contact
Status Completed
Phase
Start date November 1, 2017
Completion date March 31, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05060991 - Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients Phase 4
Active, not recruiting NCT01446978 - Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs Phase 2
Completed NCT03855176 - Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients Phase 4
Not yet recruiting NCT05923970 - Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
Recruiting NCT05019248 - Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
Completed NCT03467074 - Role of Interferon-λ and Vaccine Response
Completed NCT05124509 - Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
Completed NCT05791851 - Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
Completed NCT05030974 - RECOVAC Repeated Vaccination Study Phase 4
Completed NCT03930017 - Pregnancy, Arsenic and Immune Response
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT06148025 - Antibiotics and Vaccine Immune Responses Study Phase 4
Completed NCT03368495 - Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Phase 4
Completed NCT04912661 - Iron and Vaccine Response N/A
Completed NCT04915820 - Iron and COVID-19 Vaccine Response N/A
Completed NCT04885907 - Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients Phase 4
Completed NCT03588013 - Study of Environmental Enteropathy and Malnutrition in Pakistan N/A
Completed NCT04936997 - Immune Response to the COVID-19 Vaccine Early Phase 1
Completed NCT03996538 - Vaccination Efficacy With Metformin in Older Adults Phase 1
Completed NCT02453113 - Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment N/A